62 filings
Page 3 of 4
6-K/A
l0vez7vtv91 oxcwtny5
15 Oct 21
Current report (foreign) (amended)
7:19am
6-K
tnyg377gt
15 Oct 21
Notice of General Meeting to be held on 1 November 2021
7:15am
6-K
2suocbtb81 eg
12 Aug 21
Current report (foreign)
4:38pm
6-K
hv65arh79d7qp8x
12 Aug 21
Silence Therapeutics Reports Half-Year 2021 Results
4:30pm
6-K
yje h7d3k899fie136f
15 Jun 21
Results of Annual General Meeting
4:30pm
6-K
i0mxq
7 Jun 21
Preclinical data at EHA support recently reported positive topline clinical data for SLN124 in healthy volunteers
7:15am
6-K
4s8bnt
25 May 21
Silence Therapeutics Receives Remaining $40 Million from AstraZeneca as Part of Upfront Investment for Ongoing siRNA Collaboration
6:30am
6-K
sqzx0
19 May 21
Silence Therapeutics Announces Positive Data from GEMINI Phase 1 Study of SLN124 in Healthy Volunteers
6:30am
6-K
j7dhfj 5xehl
7 May 21
Notice of Annual General Meeting
4:18pm
6-K
rr3 vmc64fv
29 Apr 21
Silence Therapeutics Announces First Patient Dosed in GEMINI II Phase I Clinical Trial for SLN124
6:30am
6-K
kc2aa
28 Apr 21
Silence Therapeutics Achieves Another Research Milestone Payment from Mallinckrodt Collaboration for Complement-Mediated Diseases
7:46am
6-K
sxjqv24dgaky
19 Apr 21
Current report (foreign)
8:01am
6-K
9md2qkw
30 Mar 21
Silence Therapeutics Reports Full-year 2020 Results
7:47am
6-K
p0d9k1 chej
26 Feb 21
Current report (foreign)
8:28am
6-K
qjkn0
17 Feb 21
Current report (foreign)
8:51am
6-K
gqq0vl4lh o55vu
5 Feb 21
Securities Purchase Agreement
9:40pm
6-K
4rl73ls
6 Jan 21
Silence Therapeutics Appoints Craig Tooman as Chief Financial Officer
7:33am
6-K
p2n0 x1bbd1oef
16 Nov 20
Silence Therapeutics Presents Positive Pre-Clinical Data for SLN360 for the Treatment of Elevated Lipoprotein(a) at American Heart Association 2020
7:00am
6-K
uu1lvck42z7lbt2
2 Nov 20
Silence Therapeutics Appoints Dr. Marie Wikström Lindholm to its
7:31am
6-K
o4c262it0
8 Oct 20
Silence Therapeutics Announces Change to Executive Leadership Team
7:35am